Biological and molecular characterization of PNH‐like lymphocytes emerging after Campath‐1H therapy
- 1 March 2001
- journal article
- case report
- Published by Wiley in British Journal of Haematology
- Vol. 112 (4) , 969-971
- https://doi.org/10.1046/j.1365-2141.2001.02677.x
Abstract
Campath‐1H, an anti‐CD52 monoclonal antibody, is therapeutically active in lymphoproliferative and autoimmune diseases. After Campath‐1H therapy, lymphocytes with a paroxysmal nocturnal haemoglobinuria (PNH) phenotype have been reported to emerge. We characterized a PNH‐like lymphocyte population emerging after Campath‐1H therapy, in a patient with fludarabine refractory B‐cell chronic lymphocytic leukaemia (B‐CLL). We demonstrated a reduction in PIG‐A mRNA levels compared with controls, and of all cytokines tested [interleukin (IL)‐4, IL‐13, IL‐2, interferon(IFN)‐γ, IL‐6, IL‐10, and tumour necrosis factor (TNF)‐α], except transforming growth factor (TGF)‐β. Given the inhibitory activity of TGF‐β, its elevated levels may contribute to the selective pressure of Campath‐1H, leading to the emergence of PNH‐like lymphocytes.Keywords
This publication has 10 references indexed in Scilit:
- The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatmentBritish Journal of Haematology, 1999
- High Incidence of Transiently Appearing Complement-Sensitive Bone Marrow Precursor Cells in Patients with Severe Aplastic Anemia - A Possible Role of High Endogenous IL-2 in Their SuppressionActa Haematologica, 1999
- Reduced IL-4 and interferon-gamma (IFN-γ) expression by CD4 T cells in patients with chronic lymphocytic leukaemiaClinical and Experimental Immunology, 1999
- Cross‐linking of the CAMPATH‐1 antigen (CD52) mediates growth inhibition in human B‐ and T‐lymphoma cell lines, and subsequent emergence of CD52‐deficient cellsImmunology, 1998
- Diminished production of interleukin‐6 in chronic lymphocytic leukaemia (B‐CLL) cells from patients at advanced stages of diseaseBritish Journal of Haematology, 1998
- Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanismBiochemical Journal, 1997
- Emergence of CD52 −, glycosyiphosphatidylinositol-anchor deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatmentInternational Immunology, 1996
- Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B- cell non-Hodgkin lymphomaBlood, 1995
- Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin-6 productionBlood, 1993